Answers are grounded in this paper and cite their sources.
In this issue of Biology of Blood and Marrow Transplantation Alatrash and colleagues publish the results of allogeneic hematopoietic cell transplantation in 79 patients with acute myeloid leukemia or myelodysplasia age 55 to 76 (median = 58 years) using a conditioning regimen of intravenous fludarabine (40 mg/m2) and busulfan (130 mg/m2) (FLU/BU) each daily from day −6 through day −3, with graft-vs-host disease prophylaxis of tacrolimus and methotrexate (plus antithymocyte globulin with unrelated donors) [1].
No takes yet. Share an insight, caveat, or question.
Frederick R. Appelbaum (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: